The U.S. Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) to Thermo Fisher Scientific for the company's multi-infection TaqPath polymerase chain reaction (PCR) kit in differentiating the novel coronavirus from influenza.
Thermo Fisher's TaqPath COVID-19, Flu A, Flu B Combo Kit is a real-time PCR test for the detection and differentiation of RNA from the novel coronavirus and flu viruses that have been circulating. The test is effective for differentiating these infections, the company said.
